Literature DB >> 9123215

Rejection of Fas ligand-expressing grafts.

K Seino1, N Kayagaki, K Fukao, K Okumura, H Yagita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9123215     DOI： 10.1016/s0041-1345(96)00421-6

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  5 in total

1.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.

Authors:  Peter J Dupont; Anthony N Warrens
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

Review 3.  Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection?

Authors:  J Allison; K Seino; H Yagita
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Diagnostic Performance of Fas Ligand mRNA Expression for Acute Rejection after Kidney Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Baoli Heng; Hongwen Ding; Haolin Ren; Liping Shi; Jie Chen; Xun Wu; Caiyong Lai; Ganshen Yu; Yin Xu; Zexuan Su
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

5.  T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis.

Authors:  Zhenyue Hao; Brigitte Hampel; Hideo Yagita; Klaus Rajewsky
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.